SCHEMBL23999985

SCHEMBL23999985

Nc1ccc(-c2nc3cc(Nc4ccncc4)cnc3[nH]2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAD52 P43351 1/20 0.47
MAPT P10636 7/20 0.43
SMN1; SMN2 Q16637 6/20 0.43
ALDH1A1 P00352 6/20 0.43
MEN1 O00255 5/20 0.43
KMT2A Q03164 5/20 0.43
KDM4E B2RXH2 4/20 0.43
NPC1 O15118 4/20 0.43
RAB9A P51151 3/20 0.43
GLA P06280 2/20 0.43
RECQL P46063 2/20 0.43
RXFP1 Q9HBX9 2/20 0.43
GFER P55789 2/20 0.43
GAA P10253 2/20 0.43
MAPK14 Q16539 2/20 0.42
MAPK13 O15264 1/20 0.42
ALOX5 P09917 1/20 0.42
GCGR P47871 1/20 0.42
MAPK12 P53778 1/20 0.42
MAPK11 Q15759 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23999988 0.81 ALDH1A1 (0.57) MAPTSMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL24011225 0.81 RAD52 (0.53) RAD52MAPTSMN1; SMN2ALDH1A1MEN1
SCHEMBL983953 0.79 ALDH1A1 (0.45) MAPTSMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL5621043 0.79 ALDH1A1 (0.54) MAPTSMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL23999512 0.76 MEN1 (0.54) RAD52MAPTSMN1; SMN2ALDH1A1MEN1
SCHEMBL4843784 0.75 MMP2 (0.56) MAPTSMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL24075230 0.74 KIT (0.45) TNKSTNKS2
SCHEMBL23999984 0.74 MAPKAPK2 (0.51)
SCHEMBL18616895 0.72 ALDH1A1 (0.51) MAPTSMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL985864 0.72 ALDH1A1 (0.47) MAPTSMN1; SMN2ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295114-A1 AKT3 MODULATORS Georgiamune Inc. 2023-09-21 US disclosed
US-20230219927-A1 AKT3 MODULATORS Georgiamune Inc. 2023-07-13 US disclosed
US-20230219927-A1 AKT3 MODULATORS Georgiamune Inc. 2023-07-13 US disclosed
US-20230183226-A1 AKT3 MODULATORS Georgiamune Inc. 2023-06-15 US disclosed
US-20230183226-A1 AKT3 MODULATORS Georgiamune Inc. 2023-06-15 US disclosed
WO-2023081845-A1 AKT3 MODULATORS GEORGIAMUNE LLC (US) 2023-05-11 WO disclosed
WO-2023081854-A1 AKT3 MODULATORS GEORGIAMUNE LLC (US) 2023-05-11 WO disclosed
WO-2021226458-A1 AKT3 MODULATORS GEORGIAMUNE LLC (US) 2021-11-11 WO disclosed
WO-2021226519-A1 AKT3 MODULATORS GEORGIAMUNE LLC (US) 2021-11-11 WO disclosed
WO-2021226517-A1 AKT3 MODULATORS GEORGIAMUNE LLC (US) 2021-11-11 WO disclosed
WO-2021226477-A1 AKT3 MODULATORS GEORGIAMUNE LLC (US) 2021-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295114-A1 AKT3 MODULATORS AKT3, AKT2, MTOR RAD52 4364/4885MAPT 3962/4885SMN1; SMN2 1945/4885
US-20230183226-A1 AKT3 MODULATORS AKT3, AKT2, MTOR RAD52 4416/4885MAPT 3999/4885SMN1; SMN2 2070/4885
US-20230219927-A1 AKT3 MODULATORS AKT3, AKT2, PIK3CA RAD52 4094/4885MAPT 3976/4885SMN1; SMN2 2169/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.